ClinicalTrials.gg

Program

EGFR/HER2 Mutant-selective Inhibitor BH-30643

Also written as “BH-30643” and “BH-30643 combo therapy with Carboplatin/Pemetrexed”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by BlossomHill Therapeutics.

Furthest: phase 2, since Nov 19, 20241 company-led study, 1 open or runningNext primary completion: Jan 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BlossomHill Therapeutics11 open or runningphase 2since Nov 19, 2024Nov 19, 2024Jan 31, 2029phase 2 · NCT06706076

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2024First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06706076 · 675 planned · United States, Australia, Canada and more

Ahead

  1. Jan 31, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06706076

TargetBeta

EGFR →ERBB2 →read by rule
“An orally bioavailable, mutant-selective, reversible macrocyclic inhibitor of human epidermal growth factor receptor (EGFR) and epidermal growth factor receptor 2 (HER2), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
sunvozertinibruleDizal Pharmaceuticalsphase 312
sevabertinibruleBayerphase 38
enozertinibruleoric-pharmaceuticalsphase 23
GENSCI139ruleChangchun GeneScience Pharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06706076Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2RecruitingJan 31, 2029675

How it is read

Names in the registry

  • “BH-30643”, 2 entries
  • “BH-30643 combo therapy with Carboplatin/Pemetrexed”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.